Orano Med
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Orano Med sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Orano Med: 4 sponsored US clinical trials, 1 recruiting.
Orano Med sponsors 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is mCRPC (Metastatic Castration-resistant Prostate Cancer), with 1 trials.
Upper-quartile sponsor footprint
Orano Med sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
NCT05283330
Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients
NCT05153772
Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET
NCT03466216
Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy
NCT01384253
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 1 |
Therapeutic Areas
What is open in the Orano Med pipeline
1 recruiting of 4 indexed (25% open); 1 completed (25%).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: mCRPC (Metastatic Castration-resistant Prostate Cancer) (1 trial), 7 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Orano Med: open-pipeline peers nationwide
Peers matched on 4 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
Orano Med sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 25% open enrollment (± trial volume)
- AB Science · 25% recruiting · 8 trials
- Abbott Point of Care · 25% recruiting · 8 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
Related
What to do with this Orano Med page
4 registered trials is a research-attention snapshot, not an endorsement of Orano Med or any single study.
- 1 of Orano Med's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- mCRPC (Metastatic Castration-resistant Prostate Cancer) is the condition Orano Med studies most, compare against other sponsors active in the same condition before evaluating a specific study. See mCRPC (Metastatic Castration-resistant Prostate Cancer) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Orano Med pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.